Improving outcome through two decades in childhood ALL in the Nordic countries:: the impact of high-dose methotrexate in the reduction of CNS irradiation

被引:231
作者
Gustafsson, G [1 ]
Schmiegelow, K
Forestier, E
Clausen, N
Glomstein, A
Jonmundsson, G
Mellander, L
Mäkipernaa, A
Nygaard, R
Saarinen-Pihkala, UM
机构
[1] Astrid Lindgren Hosp, Karolinska Inst, Childhoos Canc Res Unit, S-17176 Stockholm, Sweden
[2] Rigshosp, Juliane Marie Ctr, Dept Pediat, Copenhagen, Denmark
[3] Univ Hosp, Dept Pediat, Umea, Sweden
[4] Univ Hosp, Skejby Hosp, Dept Pediat, Aarhus, Denmark
[5] Natl Hosp, Dept Pediat, Oslo, Norway
[6] Univ Hosp, Dept Pediat, Reykjavik, Iceland
[7] Univ Hosp, Queen Sylvia Childrens Hosp, Dept Pediat, Gothenburg, Sweden
[8] Univ Hosp, Dept Pediat, Tampere, Finland
[9] Univ Hosp, Dept Pediat, Trondheim, Norway
[10] Univ Hosp, Dept Pediat, Kuopio, Finland
关键词
leukemia; lymphocytic; acute; incidence; long-term follow-up; prognostic factors;
D O I
10.1038/sj.leu.2401961
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this population-based material from the five Nordic countries (Denmark, Finland, Iceland, Norway and Sweden), 2860 children below 15 years of age were diagnosed with acute lymphoblastic leukemia (ALL) from July 1981 to June 1998. The annual incidence was 3.9/100000 children and was stable throughout the study period. The development from regional or national protocols to common Nordic treatment protocols for all risk groups was completed in 1992 through a successive intensification with multidrug chemotherapy, including pulses of methotrexate in high doses and avoidance of cranial irradiation in most children. The overall event-free survival (EFS) at 5 years has increased from 56.5 +/- 1.7% in the early 1980s to 77.6 +/- 1.4% during the 1990s. The main improvements were seen in children with non-high risk leukemia. In high-risk patients, progress has been moderate, especially in children with high WBC (greater than or equal to 100 x 10(9)/l) at diagnosis. During the last time period (January 1992-June 1998), only 10% of the patients have received cranial irradiation in first remission, while 90% of the patients have received pulses of high dose methotrexate (5-8 g/m(2)) isolated or combined with high-dose cytosine arabinoside (total dose 12 g/m(2)) plus multiple intrathecal injections of methotrexate as CNS-targeted treatment, not translating into increased cumulative incidence of CNS relapse.
引用
收藏
页码:2267 / 2275
页数:9
相关论文
共 22 条
[1]   Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia [J].
Coustan-Smith, E ;
Behm, FG ;
Sanchez, J ;
Boyett, JM ;
Hancock, ML ;
Raimondi, SC ;
Rubnitz, JE ;
Rivera, GK ;
Sandlund, JT ;
Pui, CH ;
Campana, D .
LANCET, 1998, 351 (9102) :550-554
[2]   Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia:: a Nordic series comparing two treatment periods [J].
Forestier, E ;
Johansson, B ;
Gustafsson, G ;
Borgström, G ;
Kerndrup, G ;
Johannsson, J ;
Heim, S .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (01) :147-153
[3]  
Gustafsson G, 1998, ACTA PAEDIATR, V87, P1151
[4]   A POPULATION-BASED STUDY OF CHILDREN WITH STANDARD RISK ACUTE LYMPHOBLASTIC-LEUKEMIA IN THE 5 NORDIC COUNTRIES - A FOLLOW-UP OF 230 PATIENTS [J].
GUSTAFSSON, G ;
BERGLUND, G ;
GARWICZ, S ;
HERTZ, H ;
JONMUNDSSON, G ;
MOE, PJ ;
SALMI, TT ;
SEIP, M ;
SIIMES, MA ;
YSSING, M .
ACTA PAEDIATRICA SCANDINAVICA, 1989, 78 (01) :104-109
[5]   A POPULATION-BASED STUDY OF CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA DIAGNOSED FROM JULY 1981 THROUGH JUNE 1985 IN THE 5 NORDIC COUNTRIES - INCIDENCE, PATIENT CHARACTERISTICS AND TREATMENT RESULTS [J].
GUSTAFSSON, G ;
GARWICZ, S ;
HERTZ, H ;
JOHANESSON, G ;
JONMUNDSSON, G ;
MOE, PJ ;
SALMI, T ;
SEIP, M ;
SIIMES, MA ;
YSSING, M ;
AHSTROM, L .
ACTA PAEDIATRICA SCANDINAVICA, 1987, 76 (05) :781-788
[6]   In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia [J].
Kaspers, GJL ;
Veerman, AJP ;
Pieters, R ;
VanZantwijk, CH ;
Smets, LA ;
VanWering, ER ;
DenBerg, AV .
BLOOD, 1997, 90 (07) :2723-2729
[7]   MERCAPTOPURINE METABOLISM AND RISK OF RELAPSE IN CHILDHOOD LYMPHOBLASTIC-LEUKEMIA [J].
LILLEYMAN, JS ;
LENNARD, L .
LANCET, 1994, 343 (8907) :1188-1190
[8]  
MOE P J, 1984, European Paediatric Haematology and Oncology, V1, P19
[9]   METHOTREXATE INFUSIONS IN POOR PROGNOSIS ACUTE LYMPHOBLASTIC-LEUKEMIA .2. HIGH-DOSE METHOTREXATE (HDM) IN ACUTE LYMPHOBLASTIC-LEUKEMIA IN CHILDHOOD - A PILOT-STUDY FROM APRIL 1981 [J].
MOE, PJ ;
WESENBERG, F ;
KOLMANNSKOG, S .
MEDICAL AND PEDIATRIC ONCOLOGY, 1986, 14 (03) :189-190
[10]  
MOE PJ, 1981, ACTA PAEDIATR SCAND, V70, P73, DOI 10.1111/j.1651-2227.1981.tb07176.x